Skip to content

Do Cardiac Health: Advanced New Generation Ecosystem - Phase 2

Do Cardiac Health: Advanced New Generation Ecosystem - Phase 2

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03178305
Acronym
Do CHANGE-2
Enrollment
250
Registered
2017-06-06
Start date
2017-07-27
Completion date
2018-07-31
Last updated
2018-07-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases, Life Style, Quality of Life

Brief summary

The Do CHANGE service is designed for cardiac patients who could benefit from lifestyle change and a better disease management. The study aims to support patients with behavior change by providing them with devices and behavioral intervention in order to facilitate long-term behavior change.

Detailed description

The focus of the Do CHANGE project is on empowering individuals with high blood pressure, ischemic heart disease or heart failure with tools and services to optimally monitor and manage their real-time health condition and disease. The innovative approach of the Do CHANGE project also involves the patients' surrounding health ecosystem in the process. The traditional difficulties of therapy adherence in a physician-centred care system are radically abandoned and replaced by a patient-centred approach. The approach advocated by Do CHANGE project focuses on the needs of the patient by not only providing them with innovative tools that assess the patient's real-time health condition, but also offer a variety of behavioural alternatives. The main hypothesis of the Do CHANGE project is that patients' disease self-management and lifestyle will improve as compared to self-management of patients who receive the care as usual.

Interventions

BEHAVIORALDo CHANGE

Besides the behavior change programme (Do Something Different) 1. All patients will receive: Fitbit, Beddit, Care-portal, Do CHANGE app (including dietary habits picture taking), CookiT (smart spatula that monitors cooking behavior) 2. patients with heart failure will, in addition to the above mentioned, be offered a weight scale, blood pressure monitor, and FluiT (smart cup to measure fluid intake). 3. Patients with hypertension will also be offered a bloodpressure monitor. Data from these devices will be gathered and visible for patients (in patient portal) and for their health care provider (health care provider portal). In case of negative results the patient will be contacted by their health care provider (usually the cardiologist). Once every week the patients will be contacted to discuss their progress and will be given feedback about their dietary intake.

Sponsors

European Commission
CollaboratorOTHER
Badalona Serveis Assistencials
CollaboratorOTHER
Smart Homes
CollaboratorUNKNOWN
ONMI
CollaboratorUNKNOWN
Eindhoven University of Technology
CollaboratorOTHER
Docobo Ltd.
CollaboratorINDUSTRY
Do Something Different
CollaboratorOTHER
Buddhist Tzu Chi General Hospital
CollaboratorOTHER
The Industrial Technology Research Institute
CollaboratorOTHER
Elisabeth-TweeSteden Ziekenhuis
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

Randomized controlled trial where patients will be randomly (2:2) assigned to the intervention vs control group.

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* age 18-75 years * diagnosed with CAD, HF or HT * having at least two of the following risk factors: smoking, positive family history, increased cholesterol, diabetes, sedentary lifestyle, psychosocial risk factors. * Patients should also have access to the Internet and have a smartphone (and sufficient knowledge on using personal computer or smartphone) * sufficient knowledge of the countries' native language. * Additional inclusion criteria for HF patients only is to have a previous diagnosis of systolic or diastolic heart failure and experience HF symptoms (e.g. shortness of breath, chest pain, exhaustion).

Exclusion criteria

* significant cognitive impairments (e.g. dementia) * patients who are on the waiting list for heart transplantation * life expectancy \<1 year * life threatening comorbidities (e.g. cancers), * a history of psychiatric illness other than anxiety/depression * patients who do not have access to internet * patients with insufficient knowledge of the local pilot language (Dutch, Chinese and Catalonian).

Design outcomes

Primary

MeasureTime frameDescription
Behavioral flexibility3 monthsWith the Do Something Different purpose designed questionnaire changes in behavioral flexibility will be measured. This programme has previously shown to be effective in changing lifestyle behaviors among physically healthy subjects.
Quality of Life (QoL)3 monthsQuality of life will be assessed with the WHOQoL-Bref which is a validated questionnaire and taps into different domains of quality of life.
Lifestyle3 monthsLifestyle change will be measured with the HPLP-II questionnaire which assesses multiple domains of lifestyle. This will make it possible to compare the two groups.

Secondary

MeasureTime frameDescription
Satisfaction, usability, and acceptance of the intervention6 monthsFor this purpose the UTAUT-2 questionnaire will be used
Health care utilization6 monthsPurpose designed questionnaires will be administered to assess health care utilization
Cost effectiveness6 monthsthe EQ-5D questionnaire will be administered in order to estimate the cost-effectivenss of the intervention.

Other

MeasureTime frameDescription
Identification of Subgroups that benefit6 monthsIdentifying subgroups of patients who are more likely to benefit from this type of approach. Patients with certain demographic and/or psychological profile (Type D personality which will be measured with the DS14 questionnaire) might be more likely to benefit than others.
Effects of intervention on physiological data6 monthsMeasuring change in patients' physiological data (in the intervention group) in for example, sleep patterns or patients' ECGs, as a result of the intervention.

Countries

Spain, Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026